Inovio, MedImmune partner under $45m DARPA Ebola contract
This article was originally published in Scrip
Executive Summary
Shares of Inovio Pharmaceuticals got a 8.6% boost on 8 April on the news the firm was named the prime contractor by the US Defense Advanced Research Projects Agency (DARPA) to lead a consortium of companies and academic researchers tapped to develop multiple treatment and prevention approaches against Ebola – a disease that has infected more than 25,500 people in the current outbreak in West Africa, killing over 10,500.